Diabetic foot ulcer and its complications are becoming more and more serious problems
threatening people's health. In the last decade, multiple growth factors and their combined …

Diabetic foot ulceration is a major complication of diabetes mellitus. Recombinant human
epidermal growth factor (rhEGF) is used topically in the treatment of diabetic foot ulcers. This …

To evaluate the efficacy and safety of recombinant human epidermal growth factor (rhEGF)
in treating diabetic foot ulcers (DFUs), we conducted both database searches (PubMed …

Diabetic foot ulcers (DFUs) are one the common complications of diabetes mellitus. Many
trials were performed to evaluate the effect of recombinant human epidermal growth factor …

The healing process in diabetic foot ulcer (DFU) is hindered by factors such as chronic
inflammation, defects in fibroblast function, poor angiogenesis, and lack of cell migration …

Aims This study was conducted to evaluate the efficacy and safety of a novel spray-applied
growth factor therapy containing recombinant human epidermal growth factor (rhEGF) for the …

To investigate the efficacy and safety of recombinant human epidermal growth factor
(rhEGF) in advanced diabetic foot ulcers (DFU) A double‐blind trial was carried out to test …

Background After several exploratory and confirmatory clinical trials, the intralesional
administration of human recombinant epidermal growth factor (hrEGF) has been approved …

Foot ulceration is among the most significant complications of diabetes. It is estimated that
15% of the diabetic patients develop ulcers at some point in their lives (Reiber, 1996). The …

The intralesional injection of recombinant human epidermal growth factor (rhEGF) has been
recently approved and introduced in several countries for the treatment of advanced diabetic …